Registry for patients with acute myocarditis
Acute Myocarditis Registry With Prognostic, Histologic, Immunologic, Biological, Imaging and Clinical Assessment
Assistance Publique - Hôpitaux de Paris · NCT04844151
This study is tracking the health and recovery of patients with acute myocarditis to see how different factors affect their long-term outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1400 (estimated) |
| Ages | 15 Years and up |
| Sex | All |
| Sponsor | Assistance Publique - Hôpitaux de Paris (other) |
| Locations | 1 site (Paris) |
| Trial ID | NCT04844151 on ClinicalTrials.gov |
What this trial studies
The AMPHIBIA study is an observational cohort that aims to describe the various characteristics of patients hospitalized for acute myocarditis and evaluate their association with long-term prognosis. It will analyze clinical, biological, imaging, genetic, and histological data from up to 1,400 patients over a 20-year period. This comprehensive registry will provide valuable insights into the disease's progression and outcomes, helping to improve understanding and management of acute myocarditis.
Who should consider this trial
Good fit: Ideal candidates for this study are patients hospitalized with confirmed acute myocarditis.
Not a fit: Patients with severe valvulopathy, complex congenital cardiopathy, previous heart transplants, or significant coronary disease may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of acute myocarditis and improve patient prognosis through better-informed treatment strategies.
How similar studies have performed: While there have been studies on myocarditis, this registry approach focusing on a comprehensive set of data over an extended period is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Acute myocarditis confirmed by cardiac magnetic resonance according to Lake Louise modified criteria or by endomyocardial biopsy according to histologic, immunologic and immunohistochemic criteria. * affiliation to the French Health Care System "Sécurité sociale" Exclusion Criteria: * Severe valvulopathy * Complex congenital cardiopathy * Previous heart transplant * Known significative coronary disease
Where this trial is running
Paris
- Hôpital Pitié-Salpêtrière — Paris, France (RECRUITING)
Study contacts
- Study coordinator: Mathieu Kerneis, MD
- Email: mathieu.kerneis@aphp.fr
- Phone: +33142163001
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Myocarditis, Cardiomyopathies, Inflammatory heart disease, Magnetic resonance imaging, Viral